Event Date/Time: Oct 20, 2009 End Date/Time: Oct 21, 2009
Registration Date: Oct 20, 2009
Early Registration Date: Jul 31, 2009
Report as Spam


The 17th Forum on Biotech Patenting from C5 will once again equip you with cutting edge information on the most pressing issues affecting biotechnology. Our outstanding panel of experts comprising influential regulators and experienced biotech patent counsel will share with you the latest strategies you can immediately incorporate into your practice to maximise the scope and safety of your biotech patent portfolio in today’s challenging conditions.

Be there for our Special Keynote Address by Lord Hoffmann
Law Lord, House of Lords, London Parliament

Confirmed speakers:
• Dr Martina Blasi, Lawyer, European Patent Office
• Immac Thampoe, Senior Patent Director, Schering Plough
• Vineet Kohli, Patent Counsel, Merck & Co
• Rob Aerts, Principal Patent Attorney, Solvey Pharmaceuticals
• Ian Bryan, IP Counsel, GE Healthcare
• Jurgen Meier, Partner, Vossius & Partner
• Jane Gunnison, Partner, Ropes & Gray
• Anthony Chen, Partner, Jones Day (China)
• Archana Shanker, Senior Partner-Patents, Anand and Anand (India)

Topics to be covered include:
• The status and impact of major EPO and national court cases, including Eli Lily vs HGS, Kubin and Bilski
• Hear directly from the EPO on patentability, including latest requirements and key policy changes
• How to adapt your patent practice in response to EPO rule changes on divisional applications and search process
• Assessment of the impending Enlarged Board decision on second medical use and dosing regimens
• Update on recent developments and patentability requirements in China, India and Brazil and a comparative assessment with European and US standards
• An exploration of the application of the WARF decision in subsequent downstream stem cell cases
• Analysis of Recent Decisions Upswing in Cases Involving Supplementary Protection Certificates
• Guidance on Securing Patents for Antibodies when there are Heightened Inventive Step Requirements
• The latest European and US Developments Requirements in Patenting Biosimilars
• Cross-Jurisdictional Litigation: Update on recent procedural developments and the latest litigation management strategies